Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

Linglong Yin, Youhong Liu, Yuchong Peng, Yongbo Peng, Xiaohui Yu, Yingxue Gao, Bowen Yuan, Qianling Zhu, Tuoyu Cao, Leye He, Zhicheng Gong, Lunquan Sun, Xuegong Fan, Xiong LiJournal of Experimental & Clinical Cancer Research 2022 · DOI · OpenAlex

This article serves as a formal correction to a 2018 study investigating novel therapeutic combinations for prostate cancer. While the primary objective of this update is to rectify a data visualization error in the original publication, it underscores a significant discovery: the synergistic potential of combining PARP and HDAC inhibitors to disrupt cancer cell survival.

Addressing Resistance via Synthetic Lethality

Prostate cancer (PCa) often develops resistance to conventional treatments by reinforcing its DNA damage repair (DDR) pathways. The original research focused on the UHRF1/BRCA1 complex, a critical hub that allows cancer cells to repair lethal DNA breaks.

To overcome this, researchers proposed a "synthetic lethality" strategy using two specific inhibitors:

  1. Veliparib (VEL): A PARP inhibitor that blocks enzymes essential for repairing single-strand DNA breaks.
  2. SAHA (Vorinostat): An HDAC inhibitor that alters gene expression and destabilizes key proteins involved in repair.

By targeting these two pathways simultaneously, the researchers aimed to overwhelm the cancer cell's repair machinery more effectively than either drug could achieve alone.

Validating Programmed Cell Death

The study utilized several prostate cancer cell lines (including LNCaP, C4-2, and CWR22Rv1) to test the efficacy of the combination therapy. Two primary methods were used to confirm apoptosis (programmed cell death):

  • Western Blotting: This technique measures the levels of cleaved PARP. When a cell undergoes apoptosis, the PARP protein is cleaved; thus, increased levels of the cleaved form serve as a definitive biochemical marker of cell death.
  • Flow Cytometry: Using Annexin V/PI staining, researchers could quantitatively sort and count live versus dying cells.
Western blot analysis of CWR22Rv1 cells showing increased cleaved-PARP levels in the combination treatment group (SAHA + VEL).

Key Results: A Synergistic Effect

The most significant finding was the "1+1=3" effect observed when combining SAHA and veliparib. In all tested models, the combination treatment induced a statistically significant increase in apoptosis compared to control groups or single-drug treatments ($p < 0.01$).

Bar graph illustrating the percentage of apoptotic C4-2 cells. The combination of SAHA and VEL shows a significantly higher rate of apoptosis compared to individual treatments.

Biochemical analysis consistently supported these findings, showing that the combination therapy destabilized the UHRF1/BRCA1 complex, preventing the cancer cells from recovering from DNA damage.

The Importance of Scientific Accuracy

The publication of this correction specifically addresses a clerical error where incorrect flow cytometry plots were displayed for the C4-2 cell line. The authors emphasize that while the visual representation was updated, the underlying data and the study's original conclusions—that SAHA and veliparib synergistically co-target the DDR complex—remain robust and unchanged. This correction ensures the integrity of the scientific record for future research into prostate cancer therapies.

Summary updated

BibTeX
@article{yin2022correction,
  author = {Linglong Yin and Youhong Liu and Yuchong Peng and Yongbo Peng and Xiaohui Yu and Yingxue Gao and Bowen Yuan and Qianling Zhu and Tuoyu Cao and Leye He and Zhicheng Gong and Lunquan Sun and Xuegong Fan and Xiong Li},
  title = {{Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2022},
  doi = {10.1186/s13046-022-02290-9},
}
Figure